Maven Securities LTD Invests $2.55 Million in Guardant Health, Inc. $GH

Maven Securities LTD acquired a new position in Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 25,000 shares of the company’s stock, valued at approximately $2,554,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Next Century Growth Investors LLC bought a new stake in shares of Guardant Health in the 4th quarter worth $1,888,000. First Turn Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth $27,750,000. Entropy Technologies LP raised its stake in shares of Guardant Health by 140.3% in the 4th quarter. Entropy Technologies LP now owns 17,093 shares of the company’s stock worth $1,746,000 after buying an additional 9,979 shares in the last quarter. Arax Advisory Partners raised its stake in shares of Guardant Health by 61.5% in the 4th quarter. Arax Advisory Partners now owns 733 shares of the company’s stock worth $75,000 after buying an additional 279 shares in the last quarter. Finally, Bullseye Asset Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth $102,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ:GH opened at $131.62 on Monday. The firm has a market capitalization of $17.45 billion, a price-to-earnings ratio of -38.83 and a beta of 1.61. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $134.28. The business’s fifty day moving average price is $103.51 and its 200 day moving average price is $102.08.

Insider Activity

In related news, insider John G. Saia sold 20,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the transaction, the insider directly owned 45,950 shares of the company’s stock, valued at approximately $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00. Following the transaction, the chief executive officer directly owned 1,886,504 shares in the company, valued at $207,307,924.56. The trade was a 10.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 449,238 shares of company stock valued at $51,164,492 in the last ninety days. Corporate insiders own 5.60% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on GH. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Royal Bank Of Canada initiated coverage on Guardant Health in a research report on Thursday. They set an “outperform” rating and a $185.00 target price on the stock. Wolfe Research initiated coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Robert W. Baird initiated coverage on Guardant Health in a research report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $141.95.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.